According to Boston Scientific, the Endotak Reliance 4-SITE lead system is designed to simplify the implant procedure by combining three terminals into one integrated connector, reducing the required implant area within the body.
This system, combined with the new Teligen implantable cardioverter defibrillator (ICD) and Cognis cardiac resynchronization therapy defibrillator (CRT-D), is designed to comply with the forthcoming international connector standard. The new standard will permit product compatibility across manufacturers, the company said.
The company is working with physicians to launch the system in several phases with a focus on monitoring clinical performance through post-market analysis enhanced by the Latitude patient management system.
Fred Colen, president of cardiac rhythm management at Boston Scientific, said: "We are pleased to announce CE Mark and the first human implants of the Endotak Reliance 4-SITE lead system. This new system represents the next advance for the Endotak Reliance lead family, which has demonstrated reliability in more than 350,000 implants worldwide."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index